Release Date: August 08, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you give us any color on which types of patients youre treating with LOQTORZI in NPC? Are they primarily newly diagnosed patients or are you seeing switches from other patients on off-label PD-1s? And where are you with the payer coverage access? A: The NPC launch is delivering in line with expectations, with a heterogeneous mix of patients. We have patients in later lines of therapy receiving LOQTORZI as monotherapy, and early line patients who will have longer treatment durations. Payer coverage is nearly 100% across targeted medical benefit lives, including Medicare and commercial plans. The J-code enables electronic billing and faster reimbursement, removing operational barriers.
Q: Can you tell us more about the biggest contributor driving UDENYCA unit growth and how sustained this momentum might be? A: UDENYCA's growth is driven by the commercial launch of the on-body device, broad payer coverage, and disciplined ASP management. The on-body device allows competition across the entire pegfilgrastim market, and payer coverage has nearly doubled compared to 2023. We expect continued growth in the second half of 2024, with on-body being the primary growth driver.
Q: What differences would you expect to see from using toripalimab versus atezolizumab in the triplet for HCC? And what is your next Phase 3 plan after HCC? A: Toripalimab has shown a higher overall response rate and PFS compared to atezolizumab in previous studies. We expect toripalimab to be well-suited against atezolizumab, with casdozokitug adding increased benefit. For the next Phase 3, we are focusing on non-small cell lung cancer and HCC, building on early phase study activity.
Q: How much of the NPC market is treated in NCCN centers versus the community setting, and how long will it take to penetrate the broader community? A: About 60% of NPC in the U.S. is treated in academic NCCN settings, with 40% in the community. Our LOQTORZI business is about two-thirds in hospitals. We are focused on engaging community oncologists to drive new patient acquisition across both segments.
Q: What milestones and royalties are owed to Junshi for toripalimab, and what obligations do you have for its development? A: Junshi receives a $25 million approval milestone, with half already paid, and a 20% royalty on net sales. We are not obligated to share development costs unless we choose to. The royalty extends to any toripalimab sold in the U.S., regardless of indication.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.